829 |
Does PROSPECT Support the Use of Invasive Imaging to Diagnose and Treat Vulnerable Plaque with DES? |
Gregg W. Stone |
May. 03. 10 |
828 |
My Crystal Ball - New Drug Delivery Platforms and Bioabsorbable Stents will Dominate in the Next 5-10 Years! |
Martin Bert Leon |
May. 03. 10 |
827 |
The Role of New Anti-platelet Agents: Will Prasugrel and Ticagrelor Change the DES Landscape? |
Roxana Mehran |
May. 03. 10 |
826 |
Dual-Antiplatelet Therapy Dilemmas - Drug Dosing and Duration, Rebound, and Platelet Monitoring |
Donald E. Cutlip |
May. 03. 10 |
825 |
Addressing the Lingering Concerns of Late DES Safety and Efficacy? |
Ajay J. Kirtane |
May. 03. 10 |
824 |
Introducing EXCEL: The \"Definitive\" Unprotected Left Main Randomized Trial! |
Gregg W. Stone |
May. 03. 10 |
823 |
Integrating IVUS, FFR, and Non-Invasive Imaging to Optimize PCI Outcomes |
Gary S. Mintz |
May. 03. 10 |
822 |
Cointerpoint: When is PCI an Acceptable or Preferred Alternative? |
Paul S. Teirstein |
May. 03. 10 |
821 |
Point: When is Surgery the Preferred Therapy? |
David Paul Taggart |
May. 03. 10 |
820 |
Therapy in Evolution: Percutaneous Aortic Valve Replacement |
Martin Bert Leon |
May. 03. 10 |